Galventa was the start-up selected to launch this series of events, which will take place throughout the first three months of 2021
Last week we wanted to help you PREPARE for Clinical Trials. Today, learn how you can reach success in your product’s clinical development with our package CONDUCT.
As a results-driven company, HEMEX is dedicated to improving the lives of animals, people, and the planet. Today, we are really excited to formally announce the launch of a new series of HEMEX programs to drive change by welcoming cutting-edge ideas to the global Animal Health market.
Our portfolio company Opterion Health AG announced today the successful agreement of a EUR 8.4m Bridge Financing
Round. The proceeds from this financing round will be used to complete preclinical activities and prepare for entry into Phase I. Heartfelt congratulations on your success, Opterion!
Starting on the 21st of January 2021 and during the next three months, we have organized exclusive online webinars with plenty of interesting opportunities just for you!
Learn how can you lay the groundwork for the clinical development of your product with our Contract Research Organization
The New Year is an exciting time as we all focus on goals and resolutions. At HEMEX, we are focused on bringing you solutions at each critical step of the clinical development of your product. Together we can generate the accurate evidence needed for success!
This year has been unlike any other, but at HEMEX we have continued with a positive spirit through it all. In this article, we want to take a look back at 2020 as we look ahead to all that we can accomplish next year.
2020 has turned our lives upside down. It started as an exciting yea
In times of high uncertainty like this 2020 year, it is necessary to celebrate and savor the victories. We want to congratulate our portfolio company Sleepiz for its well-deserved success in winning collaboration with one of the three Executive MBA cohorts at the beginning of 2021
Our portfolio company ASPIVIX SA announced last week the completion of and interim analysis results from its Phase I first-in-women trial. The two-phase ADVANCE Women trial is assessing the usability, efficacy, and safety of the investigational CAREVIX, the innovative device designed as a modern and gentler alternative. Warmest congratulations on your achievement, ASPIVIX!